Liraglutide vs MOTS-c
Overview
Liraglutide and MOTS-c are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Liraglutide and MOTS-c across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Liraglutide | MOTS-c | |
|---|---|---|
| Category | Weight Management & Metabolic | Weight Management & Metabolic |
| Regulatory status (US) | FDA approved | Compounding (Rx) — Apr 2026 |
| Typical dosage | 0.6-3.0 mg | 5-10 mg |
| Frequency | daily | weekly |
| Reported benefits | Weight loss, blood sugar control, cardiovascular protection | Enhanced metabolism, improved insulin sensitivity, increased exercise capacity, longevity benefits |
| Reported side effects | Nausea, GI disturbances, potential pancreatitis | Well-tolerated. Minimal reported side effects |
Key differences
Primary use. Liraglutide is categorised under Weight Management & Metabolic, while MOTS-c falls under Weight Management & Metabolic. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Liraglutide: FDA-approved. MOTS-c: not FDA-approved; compounding permitted with a prescription as of April 2026.
Dosing. Liraglutide is typically dosed at 0.6-3.0 mg (daily). MOTS-c is typically dosed at 5-10 mg (weekly).
Can you stack them?
Some protocols combine peptides, but stacking Liraglutide and MOTS-c has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Liraglutide and MOTS-c?
- Liraglutide and MOTS-c are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status. Liraglutide is FDA-approved for one or more indications, whereas MOTS-c is not FDA-approved; compounding permitted with a prescription (as of April 2026).
- What is Liraglutide used for?
- FDA-approved GLP-1 for weight loss.
- What is MOTS-c used for?
- Mitochondrial optimization.
- Can you take Liraglutide and MOTS-c together?
- Some users combine peptides within a single protocol, but stacking Liraglutide and MOTS-c has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Liraglutide or MOTS-c FDA-approved?
- Liraglutide is FDA-approved for one or more indications. MOTS-c is not FDA-approved; compounding permitted with a prescription (as of April 2026).
Read the full articles
- Liraglutide — full monograph: mechanism, research, dosing & references
- MOTS-c — full monograph: mechanism, research, dosing & references